WIPF1

Across TCGA pan-cancer cohorts, WIPF1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated WIPF1 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher WIPF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated WIPF1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

LIHC, UCEC, and ACC are the cancer types where WIPF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.105	0.786	<.001	24	view →
UCEC	DFS	Median	All	0.932	0.607	.006	24	view →
ACC	OS	Median	All	0.140	0.623	.002	12	view →
LUAD	OS	Median	III,IV	0.246	0.687	.008	9	view →
LUSC	DFS	Median	All	1.000	0.383	.018	7	view →
ESCA	OS	Median	II,III,IV	0.105	0.867	.016	6	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

WIPF1–LIHC (OS)

Open the LIHC breakdown →